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imal tubule cells.
Background. Interleukin-1 (IL-1), interleukin-6 (IL-6), and tu-
mor necrosis factor (TNF) levels are elevated in kidneys of
patients with post-diarrheal hemolytic uremic syndrome
(D1HUS) and may contribute to renal dysfunction. The renal
cellular sources of these inflammatory cytokines in D1HUS are
largely unknown, however, the proximal tubule has emerged as a
potentially important candidate. Since Shiga toxin-1 (Stx-1) has
been implicated in the genesis of D1HUS, we examined the effect
of Stx-1 on cytokine production by human proximal tubule cells.
Methods. Stx-1 cytotoxicity, protein synthesis inhibition, and
effect on IL-1, IL-6, and TNF protein release and mRNA levels
were determined. The effect of another protein synthesis inhibi-
tor, cycloheximide (CHX), on these parameters was also evalu-
ated.
Results. Stx-1 greatly increased TNF release and mRNA levels
while CHX, at concentrations that produced similar inhibition of
protein synthesis, had no effect on TNF production. In contrast,
Stx-1 and CHX caused comparable elevations in IL-1 release and
mRNA accumulation. Stx-1 and CHX also stimulated IL-6
mRNA accumulation, but only at concentrations that either were
cytotoxic or substantially blocked protein synthesis. Finally, lipo-
polysaccharide, which is likely to be elevated in the circulation of
patients with D1HUS, had no effect alone, but synergized with
Stx-1 to increase IL-1 production.
Conclusions. These results indicate that Stx-1 stimulates proxi-
mal tubule inflammatory cytokine production and that this effect
is due partially to nonspecific induction of mRNA levels as well as
activation of Stx-1-specific mechanisms.
Post-diarrheal hemolytic-uremic syndrome (D1HUS) is
the leading cause of acute renal failure in children, and the
disorder is characterized by acute renal injury, microangio-
pathic hemolytic anemia, and thrombocytopenia [1, 2].
D1HUS is associated with enteric infection by Shiga toxin
(Stx) producing organisms (typically E. coli 0157:H7) [1, 2].
Stx binds to galactose-a-1,4, galactose-b-1,4, glucose-cer-
amide (GB3), is internalized, and ultimately is cytotoxic by
virtue of directly inhibiting peptide elongation [1]. The
kidney expresses relatively high levels of GB3 as compared
to other organs, which may account, at least in part, for
renal targeting in D1HUS [3]. This apparently straightfor-
ward scenario of renal damage in D1HUS is complicated,
however, by observations suggesting that Stx may act in
concert with other factors to elicit cellular dysfunction.
Among these factors, inflammatory cytokines have
emerged as being potentially important. These cytokines,
including interleukins-1 (IL-1) and -6 (IL-6) and tumor
necrosis factor (TNF), are secreted by macrophages in
response to Stx [4]. Each of these proteins can elicit a
plethora of well characterized inflammatory responses
leading to cellular damage, renal thrombosis, fibrin accu-
mulation, and vasoconstriction [1, 2]. In addition, IL-1 and
TNF have been demonstrated to have a direct impact on
Stx-mediated cytotoxicity: both cytokines induce expression
of GB3 on the surface of human umbilical and saphenous
vein endothelial cells and up-regulate cell sensitivity to Stx
cytotoxicity [5–7]. Taken together, these observations sug-
gest that inflammatory cytokines play an important role in
the pathogenesis of cellular dysfunction in the setting of
D1HUS.
The cellular sources of inflammatory cytokines in
D1HUS are largely unknown. Serum inflammatory cyto-
kine levels in D1HUS have not been extensively studied
and may not be a valid indicator of tissue cytokine produc-
tion. Nonetheless, preliminary reports suggest IL-6 is ele-
vated in the systemic circulation of these patients, while
conflicting reports exist on whether serum TNF levels are
increased [8–10]. Macrophages produce IL-1, IL-6, and
TNF in response to Stx [4], however, macrophage infiltra-
tion in the kidney is not a prominent feature of D1HUS
[2]. Interestingly, urinary excretion of TNF and IL-6 was
very high during the acute phase of D1HUS [11], while
inoculation of gnotobiotic mice with E. coli 0157:H7 in-
creased renal TNF, IL-1, and IL-6 levels [12], suggesting
that the kidney may produce inflammatory cytokines in
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D1HUS. This notion is supported by the observation that
systemic administration of Stx to transgenic mice bearing a
chloramphenicol acetyltransferase (CAT) reporter driven
by the TNF promoter induced CAT activity primarily in the
kidney [13]. These findings then beg the question that, if
the kidney is a major source of cytokines in D1HUS, which
renal cell(s) is/are involved? Studies directed at answering
this question could be quite problematic; there are multiple
cell types within the kidney that are potential sources of
cytokine production. To narrow down the possibilities, it
seemed reasonable, at least as a first assumption, to suspect
those kidney cells that express relatively high levels of GB3,
exhibit relatively high Stx binding, and are highly respon-
sive to the toxin. Studies to date indicate that proximal
tubule cells may best meet these criteria [14]. First, Stx
binding to normal human kidney sections is most promi-
nent in renal cortical tubules [3, 15]. Second, urinary
markers of proximal tubule damage are elevated early in
the course of D1HUS [2]. Third, renal biopsies obtained
early in the course of D1HUS reveal proximal tubule, as
well as glomerular, damage [2, 16]. Fourth, since mice only
develop tubulointerstitial disease following Stx injection,
the finding that CAT reporter activity is substantially
increased in mouse kidneys (although the proximal tubule
was not specifically studied) after Stx administration sug-
gests that renal tubules may be involved [13]. Finally,
cultured human proximal tubule cells express very high
levels of GB3 and are exquisitely responsive to the toxin
[14]. Taken together, these observations provide the basis
for the first hypothesis to be tested in this study, namely,
that Stx-induced increases in inflammatory cytokine pro-
duction are due, at least in part, to toxin interaction with
the proximal tubule.
An important consideration when studying Stx actions is
that other bacterial-derived factors may contribute to cell
injury in D1HUS. One such factor, lipopolysaccharide
(LPS), is likely to be present in the blood of D1HUS
patients [1, 2] and can markedly impair renal function. LPS
alone does not cause HUS since the renal pathology in
patients with gram negative septicemia does not resemble
that of HUS [17]. LPS can, however, increase sensitivity to
Stx by up-regulating cell surface GB3 levels [6, 18]. Fur-
thermore, LPS has been shown to stimulate cytokine
release, including IL-6 and TNF, by mesangial and non-
renal endothelial cells [19–22]. Hence, the second hypoth-
esis tested in this study was that LPS acts in concert with Stx
to modulate proximal tubule cell inflammatory cytokine
production.
METHODS
Reagents
Human proximal tubule cells were obtained from Clo-
netics, Inc. (San Diego, CA, USA). Human IL-1b, IL-6,
biotinylated goat anti-human IL-1b antibody (detection),
and mouse anti-human IL-1b antibody (capture) from
R&D Systems (Minneapolis, MN, USA); mouse anti-
human TNF-a antibody (capture), biotinylated mouse anti-
human TNF-a antibody (detection), rat anti-human IL-6
antibody (capture), and biotinylated rat anti-human IL-6
antibody from Pharmingen (San Diego, CA, USA); fetal
calf serum was from Hyclone (Logan, UT, USA); random
hexamers and Taq polymerase from Boehringer Mannheim
(Indianapolis, IN, USA), RNAsin from Promega (Madi-
son, WI, USA), deoxynucleotide triphosphates from Per-
kin-Elmer (Norwalk, CT, USA); 32P-dCTP from Amer-
sham (Arlington Heights, IL, USA); and horseradish
peroxidase-Avidin D from Vector Laboratories (Burlin-
game, CA, USA). Penicillin/streptomycin, L-glutamine,
insulin, transferrin, selenium, epidermal growth factor,
murine Moloney Leukemia Virus reverse transcriptase,
DMEM:F12, M199, and DMEM were purchased from
Gibco (Grand Island, NY, USA). Unless stated otherwise,
all other reagents were obtained from Sigma Chemical Co.
(St. Louis, MO, USA).
Cell culture
Human proximal tubule cells were studied at the third
passage. Proximal tubule identity and purity has previously
been ascertained (Clonetics). Proliferating proximal tubule
cultures were maintained in 1:1 Dulbecco’s modified Eagle
media:Ham’s F12 (DMEM:F12) containing 2 mM L-glu-
tamine, 100 U/ml penicillin/streptomycin, 1 mg/ml hydro-
cortisone, 10 mg/ml insulin, 5.5 mg/ml transferrin, 6.7 mg/ml
selenium, 6.5 ng/ml L-thyroxine, 10 ng/ml epidermal growth
factor, and 10% fetal calf serum at 37°C in a 5% CO2
incubator. Barely confluent proximal tubule cell cultures
were placed in DMEM:F12 containing only L-glutamine
and penicillin/streptomycin for 24 hours prior to any exper-
imental maneuvers. Only growth-arrested cells were exam-
ined since it was desirable to avoid any confounding
influence of serum on cytokine release and since prolifer-
ating proximal tubule cells grow so fast that the cultures are
greatly overconfluent within 48 hours of becoming barely
confluent.
Cytotoxicity assay
Proximal tubule cultures in 96 well plates were exposed
to 0.01 to 1 pg/ml Stx-1, 1 mg/ml LPS, 0.01 pg/ml Stx and 1
mg/ml LPS together, or 0.1 to 100 mM cycloheximide for 4,
24, or 48 hours. At the end of the incubation period, cells
in 96 well plates were analyzed for neutral red uptake [23].
Cells were incubated in 50 mg/ml neutral red in M199 1 5%
fetal bovine serum (serum necessary to reduce neutral red
precipitation) for three hours at 37°C in a 5% CO2 envi-
ronment. Cells were rinsed in 1% formaldehyde and 1%
CaCl2 for 15 seconds, followed by addition of 50% ethanol
and 1% acetic acid for 30 to 60 minutes. Absorbance was
determined at OD450 (Molecular Devices ThermoMax
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Microplate reader, Menlo Park, CA, USA), and the results
were compared to control cells not exposed to toxin.
3H-leucine uptake
Proximal tubule cultures in 24 well plates were exposed
to 0.01 to 1 pg/ml Stx-1 or 0.1 to 100 mM cycloheximide for
4, 24, or 48 hours. Media was removed and HBSS contain-
ing 1 mCi/ml 3H-leucine added for 20 minutes at room
temperature. Cells were then rinsed with ice-cold HBSS
and solubilized in 500 ml 0.1% sodium dodecyl sulfate. A
200 ml aliquot was incubated with 25 ml 200 mg/ml bovine
serum albumin and 2 ml 10% tricarboxylic acid (TCA) for
60 minutes on ice, collected on pre-wetted GF/C filters
(Whatman, Kent, UK) through a vacuum manifold, the
filters washed with ice-cold 10% TCA and ice-cold 95%
ethanol, and air dried. Filters were added to scintillation
vials with 5 ml Ready Safe scintillation cocktail (Beckmann,
Fullerton, CA, USA) and cpm determined with a Packard
2200CA beta-counter (Downers Grove, IL, USA).
Enzyme immunometric assay
Proximal tubule cultures in six well plates containing 2 ml
of media were exposed to varying concentrations of Stx-1, 1
mg/ml LPS, LPS 1 Stx-1, or cycloheximide for 4, 24, or 48
hours. The supernatant was removed at the conclusion of
the incubation times and aliquots used for determination of
IL-1, TNF, and IL-6 levels by enzyme immunometric assay
(EIA). EIAs were performed in 96 well plates in accor-
dance with the Pharmingen General EIA Protocol. Empty
wells were coated with 50 ml of 2 mg/ml of anti-IL-1b,
anti-TNF-a, or anti-IL-6 capture antibodies in 50 mM
Tris-HCl (pH 9.5) at 4°C overnight. Unbound antibody was
rinsed away with 0.05% Tween 20 in PBS (pH 7.4) and
nonspecific binding sites blocked by incubation with 200 ml
20% bovine calf serum in phosphate buffered saline (PBS)
at 4°C overnight. After subsequent rinsing with PBS/
Tween, standards or samples were added and incubated at
4°C overnight. Sample volume was generally 100 ml with the
exception of 10 ml aliquots for IL-6 determination. Plates
were then rinsed with PBS/Tween and 100 ml detection
antibody added and incubated at room temperature (1
mg/ml biotinylated anti-TNF-a for 2 hr, 1 mg/ml biotinyl-
ated anti-IL-6 for 45 min, and 0.1 mg/ml biotinylated
anti-IL-1b for 2 hr). The concentrations and incubation
times of detection antibodies were empirically determined
to yield optimal sensitivity and accuracy. Detection anti-
body was rinsed off using PBS/Tween and 100 ml 2.5 mg/ml
horseradish peroxidase-Avidin D in 10% bovine calf serum
in PBS added for 30 minutes at room temperature. Wells
were rinsed with PBS/Tween and 100 ml 0.03% 2,29-Azino-
bis(3-ethylbenzthiazoline-6-sulfonic acid) in 0.1 M citrate
buffer (pH 4.2) containing 0.03% H2O2 added for 10
minutes at room temperature. The reaction was stopped
with 100 ml NaF and OD405 determined.
All antibodies used for EIA had no significant cross-
reactivity with other cytokines for which they were not
designed (including interleukins-1 to -8, TNF, transforming
growth factor-b, platelet-derived growth factor, acidic and
basic fibroblast growth factor, and colony stimulating fac-
tors). Anti-IL-1 and anti-TNF-a antibodies gave a linear
detection between 5 and 5000 pg/ml, and anti-IL-1b anti-
bodies gave a linear detection between 4 and 250 pg/ml.
The cells from which the supernatant was obtained were
solubilized in 0.1 N NaOH. An aliquot of NaOH was mixed
with Bradford reagent (Bio-rad, Richmond, CA, USA) and
protein concentration determined by measuring absor-
bance at 590 nm [24]. All results are expressed as ng
cytokine/mg total cell protein.
RNA analysis
Proximal tubule cultures in six well plates were exposed
to varying concentrations of Stx-1, 1 mg/ml LPS, LPS 1
Stx-1, or cycloheximide for 4, 24, or 48 hours. Cells were
then overlaid with 4 M guanidinium thiocyanate, 25 mM
sodium citrate, 1% b-mercaptoethanol, and 1% sarcosyl
(pH 7.0), aspirated several times through a 25 G needle,
and RNA phenol/chloroform extracted and quantified
spectrophotometrically [25]. A semiquantitative PCR
method was employed for determination of ET-1 mRNA
levels as previously described [26, 27]. Five micrograms of
total RNA from each sample was reverse transcribed by
incubating with 250 pmol random hexamers, 4 mM MgCl2,
400 U murine Moloney Leukemia Virus reverse transcrip-
tase, 80 U RNAsin, 500 mM deoxynucleotide triphosphates
(dNTP), 1 mM dithiothreitol, 50 mM KCl, 10 mM Tris-Cl,
and 0.01% gelatin (final buffer pH 8.3) in 50 ml for one
hour at 37°C. The reverse transcriptase was inactivated by
heating for 10 minutes at 94°C. The resultant cDNA was
amplified by polymerase chain reaction. Each sample was
measured for IL-1b, TNF-a, IL-6, and b-actin cDNA in
separate tubes using specific primers (Fig. 1). The upstream
and downstream primers for IL-1b were CCATCACAGG-
TAGTGAGACCAACC and CCATAGTCAGTAGCTCT-
GGTCCTC, respectively. These yielded a single 449 base
pair fragment which, when cycle sequenced with fluores-
ceinated primer ends (performed by Margaret Robinson in
Dr. Ray White’s laboratory at the University of Utah),
proved identical to positions 696 to 1145 in human IL-1b
cDNA. The upstream and downstream primers for TNF-a
were GGTGACCGACTCAGCGCTGAGATC and GGT-
TGCCAGCACTTCACTGTGCAG, respectively, which
yielded a 299 base pair product identical to positions 698 to
997 in human TNF-a cDNA. The upstream and down-
stream primers for IL-6 were ACATCCTCGACG-
GCATCTCAG and TGGCTTGTTCCTCACTACTCT, re-
spectively, which yielded a 246 base pair product
complementary to positions 262 to 507 in human IL-6
cDNA. Omission of reverse transcriptase prior to PCR
using primers for IL-1b, TNF-a, or IL-6 failed to yield any
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product. The upstream and downstream primers for b-actin
were TGGAGAAGAGCTATGAGCTGCCTG and GT-
GCCACCAGACAGCACTGTGTTG, respectively, which
yielded a 201 base pair cDNA fragment. PCR of genomic
DNA yielded a 289 base pair product that is complemen-
tary to positions 2499 to 2788 in the b-actin gene, confirm-
ing that this primer set spans an intron.
Polymerase chain reaction (PCR) was performed by
incubating 5 ml (approximately 0.4 mg) of sample cDNA
with 50 mM KCl, 10 mM Tris-Cl, 0.01% gelatin, 1.5 mM
MgCl2, 2.5% formamide, 2 U Taq polymerase, 200 mM each
dNTP, 100 pmoles of primers, and 0.1 mCi 32P-dCTP in 50
ml final volume (final pH 8.3 at room temperature). PCR
using b-actin, IL-6, IL-1b, or TNF-a primers were carried
out for 20, 30, 35 or 35 cycles, respectively, using a
Perkin-Elmer Cetus 9600 Gene-Amp System. This number
of cycles result in samples being obtained during the
exponential phase of amplification. Cytokine and b-actin
primers were never combined in the same tube. Twenty
microliters of the final PCR reaction was electrophoresed
on a 7% non-denaturing polyacrylamide gel. Gels were
stained with ethidium bromide and the bands correspond-
ing to the cDNA product were excised, mixed with scintil-
lation cocktail, and cpm determined on a Beckman beta
counter. A representative gel is shown in Figure 1.
Cytokine and b-actin cDNA obtained from PCR of
reverse transcribed RNA were used to generate standard
curves. The cDNA was amplified by PCR, the resultant
amplified product divided into small fractions that were, in
turn, re-amplified. After removal of primers using Magic
PCR Prep (Promega), the purity of the final product was
confirmed by electrophoresis. At the end of the purifica-
tion, the amount of standard cDNA was quantitated spec-
trophotometrically. Standard curves for b-actin or cyto-
kines were made by simultaneously amplifying sample
cDNA and, in separate tubes, standard cDNA (1021 to
1028 ng/tube). Every PCR amplification included a stan-
dard curve. All PCR consisted of simultaneous amplifica-
tion (in separate tubes) of cDNA for cytokines and b-actin.
All results are expressed as fg cytokine cDNA/ng b-actin
cDNA in order to control for the amount of RNA initially
reverse transcribed. The accuracy of this semiquantitative
PCR technique has been previously described in detail
[26–28].
Purification of Shiga toxin-1
Shiga toxin-1 was purified as previously described [14]
from E. coli HB101 containing pNAS13 (generous gift of
Alison D. O’Brian, Uniformed Services University of the
Health Sciences, Bethesda, MD, USA), a derivative of
pNAS4 [29] that contains a 3.4 kb NcoI fragment encoding
Stx-1. The crude toxin preparation from bacterial lysates
was dialyzed against 50 mM Tris-HCl (pH 8), subjected to
CL-6B DEAE-Sepharose (Pharmacia, Uppsala, Sweden)
anion-exchange chromatography using the same buffer,
and eluted with a 0 to 0.5 M NaCl gradient in the same
buffer. Fractions were pooled based on their cytotoxicity to
Vero cells and dialyzed against phosphate-buffered saline
(PBS), pH 7.4. Crude toxin was subjected to immunoaffin-
ity chromatography with a monoclonal antibody to the
B-subunit of Stx-1 (13C4; ATCC, Rockville, MD, USA)
linked to an AminoLink column (Pierce, Rockford, IL,
USA). Eluted samples were tested for cytotoxicity on Vero
cells and protein directly visualized by electrophoresis on
15% native and denaturing polyacrylamide gels. Cytotoxic
fractions were combined, concentrated and dialyzed
against PBS (pH 7.4). LPS contamination was non-detect-
able using an E-Toxate assay (Sigma). Toxin concentration
was based on spectrophotometric O.D. and Bradford pro-
tein assay.
Statistics
All data were analyzed by one way analysis of variance.
Results are expressed as mean 6 SEM. P values , 0.05 were
taken as significant.
RESULTS
Effect of Shiga toxin-1 on proximal tubule cytotoxicity
and protein synthesis
Cytotoxicity was assessed by a combination of neutral
red, total cell protein, and cell morphology. Total cell
protein paralleled neutral red data, however, it was not as
sensitive in detecting cell survival and thus is not included
in the cytotoxicity analysis. Alterations in cell morphology
Fig. 1. Representative blot of polymerase chain reaction (PCR) products
for b-actin, interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF).
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generally agreed with neutral red uptake data: marginally
toxic concentrations of Stx-1 mildly increased cytoplasmic
granularity, while higher toxin concentrations gradually
increased cytoplasmic granule number and size, caused
irregular cell borders, cell flattening, and ultimately led to
cell detachment.
Shiga toxin-1-induced alterations in proximal tubule cy-
tokine release could occur by two major mechanisms: (1)
Stx-1-specific modulation of signaling pathways; or (2)
nonspecific effects resulting from cell cytotoxicity and/or
protein synthesis inhibition. To help discriminate between
these two possibilities, a dose- and time-response for
Stx-1-induced proximal tubule toxicity was determined. As
illustrated in Figure 2, up to 48 hours incubation with 0.01
to 0.1 pg/ml Stx-1 had no detectable effect on proximal
tubule cell viability, hence these conditions were initially
identified to study “non-cytotoxic” effects of Stx-1. In
contrast, 24 to 48 hours exposure to 1 pg/ml Stx-1 caused a
50% reduction in cell survival, and these conditions were
used to study cytokine release under “cytotoxic” concen-
trations of Stx-1. Higher concentrations of Stx-1 ($10
pg/ml) caused over 90% cell death after 24 hours [11] and
were, therefore, not used in the current study. Finally, the
effect of LPS on cell survival was examined. LPS had no
cytotoxic effect alone or in combination with 0.01 pg/ml
Stx-1 (data not shown).
The Stx-1 concentrations and time courses selected
above included those that were grossly non-cytotoxic; how-
ever, the possibility remained that substantial protein syn-
thesis inhibition occurred under these “non-cytotoxic” con-
ditions. This raised the possibility that Stx-1 effects, while
not associated with reduced cell viability, could be a
nonspecific response to reduced protein synthesis. To help
examine this issue, the effect of Stx-1 on 3H-leucine uptake,
a measure of protein synthesis, by human proximal tubule
cells was studied. As demonstrated in Figure 3, exposure to
0.01 pg/ml Stx-1 for up to 48 hours had no detectable effect
on 3H-leucine uptake. Higher concentrations of the toxin,
particularly after 24 hours exposure, significantly reduced
3H-leucine incorporation into protein. Taken together with
the toxicity studies above, these findings indicated that a
range of Stx-1 concentrations and exposure times of 0.01 to
1 pg/ml and 4 to 48 hours, respectively, would cover the
spectrum from no detectable effect on cell survival or
protein synthesis to frankly cytotoxic doses. By studying
Stx-1 effects under this range of conditions, our ability to
discriminate between specific and nonspecific effects of
Stx-1 should be enhanced.
Effect of cycloheximide on proximal tubule cytotoxicity
and protein synthesis
To further evaluate the specificity of Stx-1 action, the
effect of cycloheximide (CHX), another protein synthesis
inhibitor, on inflammatory cytokine release by proximal
tubule cells was also determined. Similar to Stx-1, it was
first necessary to identify the dose- and time-dependence of
CHX cytotoxicity and protein synthesis inhibition. As
shown in Figure 4, CHX concentrations from 0.1 to 100 mM
over 4 to 48 hours achieved variable proximal tubule cell
cytotoxicity (as determined by neutral red uptake), ranging
from no detectable effect (4 hr or 0.1 mM CHX) to
approximately 60% cell death. The same CHX exposure
Fig. 2. Effects of Shiga toxin-1 (Stx-1) on human proximal tubule cell
viability. The lower the neutral red uptake, the greater the cell death. N 5
12 each data point. *P , 0.001 versus control. Symbols are: (F) 4 hr; (E)
24 hr; () 48 hr.
Fig. 3. Effect of Stx-1 on human proximal tubule cell 3H-leucine uptake
(measure of protein synthesis). N 5 3 each data point. *P , 0.001 versus
control; #P , 0.005 versus control. Symbols are: (F) 4 hr; (E) 24 hr; ()
48 hr.
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times and doses also achieved variable inhibition of protein
synthesis (as determined by 3H-leucine uptake) ranging
from no measurable effect (0.1 mM CHX) to near complete
blockade (Figure 5). Thus, 4 to 48 hours exposure to 0.1 to
100 mM CHX was used in the current study to compare the
effect of another protein synthesis inhibitor and cytotoxic
agent to that of Stx-1.
Shiga toxin-1 and cycloheximide regulation of cytokine
release and mRNA levels
Tumor necrosis factor. Proximal tubule cells released
84.2 6 17.4 ng TNF/mg total cell protein/24 hr under basal
conditions; Stx-1 augmented TNF release approximately
two- to fourfold (note that all data points are compared to
controls, not to one another; Fig. 6A). This effect occurred
primarily at non-cytotoxic concentrations of Stx-1, however,
augmented TNF release was generally associated with toxin
concentrations that inhibited protein synthesis. It should be
noted that exposure to 0.01 pg/ml Stx-1 for 24 to 48 hours
increased TNF release without detectably altering protein
synthesis or cell survival.
Proximal tubule cells contained baseline TNF mRNA
levels of 0.12 6 0.03 fg TNF cDNA/ng b-actin cDNA. Stx-1
stimulated TNF release was associated with augmented
TNF mRNA levels (Fig. 6B). The increase in TNF mRNA
was of a greater magnitude (when expressed as percent of
control) than was the rise in TNF release; this dissociation
was most evident at the highest toxin concentration. Pre-
sumably this reflects, at least in part, the effect of combined
stimulation of mRNA accumulation coincident with partial
inhibition of protein synthesis (see Discussion).
Since Stx-1 stimulation of TNF release and mRNA
accumulation occurred mainly at toxin concentrations that
partially inhibited protein synthesis, it was of interest to
compare the effect of CHX on TNF production. As shown
in Figure 7, CHX did not change TNF release or mRNA
accumulation, even at concentrations that were frankly
cytotoxic and substantially blocked protein synthesis.
Hence, it is clear that Stx-1 stimulation of TNF secretion
and mRNA levels is a specific phenomenon and not solely
a result of global protein synthesis inhibition or cellular
injury.
Interleukin-1.
Proximal tubule cells released 9.0 6 1.4 ng IL-1/mg total
cell protein/24 hr under basal conditions, and Stx-1 ele-
vated IL-1 secretion two- to fourfold (again, note that all
data points were compared to controls, and not to one
another; Fig. 8A). As for TNF, Stx-1 stimulation of IL-1
release occurred primarily at toxin concentrations that were
non-cytotoxic but did inhibit protein synthesis. Again sim-
ilar to TNF, exposure to 0.01 pg/ml Stx-1 for 24 hours
increased IL-1 release without detectably altering protein
synthesis or cell survival.
Proximal tubule cells contained baseline IL-1 mRNA
levels of 0.66 6 0.34 fg IL-1 cDNA/ng b-actin cDNA. Stx-1
stimulated IL-1 secretion was associated with elevated IL-1
mRNA levels (Fig. 8B). Like TNF, there was a relatively
greater rise in IL-1 mRNA (when expressed as percent of
control) as compared to the rise in IL-1 release, particularly
at toxin concentations that substantially inhibited protein
Fig. 4. Effect of cycloheximide on human proximal tubule cell viability.
The lower the neutral red uptake, the greater the cell death. N 5 12 each
data point. *P , 0.001 versus control. Symbols are: (F) 4 hr; (E) 24 hr; ()
48 hr.
Fig. 5. Effect of cycloheximide on human proximal tubule cell 3H-leucine
uptake (measure of protein synthesis). N 5 3 each data point. *P , 0.001
versus control for all time points at the indicated dose; #P , 0.001 for 24
and 48 hours time points at the indicated dose. Symbols are: (F) 4 hr; (E)
24 hr; () 48 hr.
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synthesis. This dissociation is most evident with exposure to
1 pg/ml Stx-1 for 48 hours where IL-1 mRNA was induced
25-fold, but IL-1 release was not elevated. Under these
conditions, Stx-1 was frankly cytotoxic as well.
Stx-1 stimulation of IL-1 release and mRNA accumula-
tion occurred primarily at toxin concentrations that re-
duced protein synthesis. To evaluate the specificity of this
response, the effect of CHX on IL-1 production by proxi-
mal tubule cells was determined. Like Stx-1, CHX in-
creased IL-1 release and mRNA levels (Fig. 9). Also like
Stx-1, CHX stimulation of IL-1 release mRNA accumula-
tion occurred mainly at concentrations that reduced pro-
tein synthesis. Thus, unlike clearly different patterns of
regulation of proximal tubule cell TNF production, the
patterns of Stx-1 and CHX modulation of proximal tubule
cell IL-1 production appeared to be similar.
Interleukin-6. Proximal tubule cells released large
amounts of IL-6 (9566 6 580 ng IL-6/mg total cell pro-
tein/24 hr under basal conditions) and the basal secretion
rate was approximately two- to three orders of magnitude
greater than that seen with IL-1 or TNF. Proximal tubule
cells also expressed relatively high levels of IL-6 mRNA
Fig. 6. Effect of Shiga toxin-1 (Stx-1) 6
lipopolysaccharide (LPS) on human proximal
tubule cell tumor necrosis factor (TNF) release
(A) and TNF mRNA levels (B). Results are
expressed as percent of control where baseline
TNF release was 84.2 6 17.4 ng TNF/mg total
cell protein/24 hours and baseline TNF mRNA
levels were 0.12 6 0.03 fg TNF cDNA/ng b-
actin cDNA. N 5 6 per TNF release data point
and N 5 3 per TNF mRNA data point. *P ,
0.05, ƒP , 0.01, #P , 0.001; all versus control.
Symbols are: (f) Stx-1 1 pg/ml; (1) Stx 0.1 pg/
ml; (M) Stx-1 0.01 pg/ml; (o) LPS; (^) LPS/Stx-
1 0.01 pg/ml.
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under baseline conditions: 6.64 6 2.75 fg IL-6 cDNA/ng
b-actin cDNA. Stx-1 had no effect on IL-1 release (as
above, all data points were compared to controls, and not
to one another; Fig. 10A), although the toxin did enhance
IL-6 mRNA accumulation (Fig. 10B). The increase in IL-6
message only occurred at toxin concentrations that inhib-
ited protein synthesis. Furthermore, IL-6 mRNA accumu-
lation was greatest when frank cytotoxicity was evident (1
pg/ml Stx-1 at 24 and 48 hr time points). It is also important
to note that Stx-1 stimulation of IL-6 mRNA accumulation
required toxin concentrations and exposure times that were
greater than those necessary to augment IL-1 or TNF
production.
The effect of CHX on proximal tubule cell IL-6 release
was also determined (Fig. 11). Like Stx-1, CHX had no
effect on IL-6 release. CHX did enhance IL-6 mRNA
accumulation, however, this only occurred under severe
conditions associated with marked cell death and protein
Fig. 7. Effect of cycloheximide on human
proximal tubule cell TNF release (A) and TNF
mRNA levels (B). Results are expressed as percent
of control where baseline TNF release was 84.2 6
17.4 ng TNF/mg total cell protein/24 hr and
baseline TNF mRNA levels were 0.12 6 0.03 fg
TNF cDNA/ng b-actin cDNA. N 5 6 per TNF
release data point and N 5 3 per TNF mRNA
data point. Symbols are: (f) 100 mM; (1) 50 mM;
(M) 10 mM; (o) 1 mM; (^) 0.1 mM.
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synthesis inhibition. Thus, CHX modulation of IL-6 pro-
duction seems to be grossly similar to that with Stx-1 in that
the cells appear to be dead or dying.
Effect of lipopolysaccharide on cytokine release and
mRNA levels
Since LPS is likely to be elevated in the circulation of
patients with HUS, and since the endotoxin has been
demonstrated to stimulate inflammatory cytokine produc-
tion by some cell types, the effect of LPS 6 Stx-1 on
proximal tubule cell IL-1, IL-6, and TNF production was
evaluated. LPS had no effect on basal or Stx-1 (0.01 pg/ml)
regulated IL-6 (Fig. 10) or TNF (Fig. 6) production. LPS
also had no effect on basal IL-1 production, although the
endotoxin did significantly enhance Stx-1-induced IL-1
release and mRNA accumulation (Fig. 8). This effect was,
however, only evident after 24 hours exposure to LPS and
Stx-1. Finally, it should be noted that the LPS concentra-
tion (1 mg/ml) was selected on the basis of its consistent
stimulation of responses in a wide variety of cell types [17].
DISCUSSION
The current study examined the effects of Stx-1 and LPS
on IL-1, IL-6, and TNF release by, and mRNA levels in,
cultured human proximal tubule cells. Several potentially
Fig. 8. Effect of Stx-1 6 LPS on human proximal
tubule cell IL-1 release (A) and IL-1 mRNA levels
(B). Results are expressed as percent of control
where baseline IL-1 release was 9.0 6 1.4 ng IL-1/
mg total cell protein/24 hr and baseline IL-1
mRNA levels were 0.66 6 0.34 fg IL-1 cDNA/ng
b-actin cDNA. N 5 6 per IL-1 release data point
and N 5 3 per IL-1 mRNA data point. *P , 0.05,
ƒP , 0.01, #P , 0.001; all versus control. DP ,
0.05 versus 0.01 pg/ml Stx-1 alone. Symbols are:
(f) Stx-1 1 pg/ml; (1) Stx 0.1 pg/ml; (M) Stx-1
0.01 pg/ml; (o) LPS; (^) LPS/Stx-1 0.01 pg/ml.
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important observations resulted from this study: (1) human
proximal tubule cells synthesize IL-1, IL-6, and TNF; (2)
Stx-1 increases inflammatory cytokine production by these
cells; (3) the mechanism of Stx-1 stimulated inflammatory
cytokine production differs between IL-1, IL-6, and TNF;
and (4) LPS enhances Stx-1 stimulated IL-1 production.
We confirm previous reports that human proximal tubule
cells produce IL-6 and TNF [30, 31] and provide the new
observation that IL-1 is also made by this cell type. The
relative quantities of inflammatory cytokine release by
proximal tubules has not previously been studied to our
knowledge. In the current study, IL-6 was released in
1000-fold greater amounts than TNF and 100-fold greater
amounts than IL-1. The increased IL-6 production was
paralleled by 10- to 50-fold greater IL-6 than IL-1 or TNF
mRNA levels. The reason for such a relatively high baseline
Fig. 9. Effect of cycloheximide on human
proximal tubule cell IL-1 release (A) and IL-1
mRNA levels (B). Results are expressed as
percent of control where baseline IL-1 release
was 9.0 6 1.4 ng IL-1/mg total cell protein/24
hr and baseline IL-1 mRNA levels were 0.66 6
0.34 fg IL-1 cDNA/ng b-actin cDNA. N 5 6
per IL-1 release data point and N 5 3 per IL-1
mRNA data point. *P , 0.05, ƒP , 0.01, #P ,
0.001; all versus control. Symbols are: (f) 100
mM; (1) 50 mM; (M) 10 mM; (o) 1 mM; (^) 0.1
mM.
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production of IL-6 is uncertain. It is possible that these cells
are somehow modified during the culture process so that
they produce greater amounts of IL-6 than seen in vivo. It
is unlikely, however, that proximal tubule cells are globally
activated during culture (in a manner similar to macro-
phage activation when stimulated with endotoxin) since
only IL-6, and not IL-1 or TNF, production is high.
Alternatively, proximal tubules may constitutively produce
IL-6 in vivo, but this has not been well studied.
Stx-1 stimulates inflammatory cytokine production by
human proximal tubule cells. The mechanisms by which
this occurs appear to vary and depends upon the specific
cytokine being studied. In the case of TNF, Stx-1 augments
release and mRNA levels by mechanisms that are, at least
in part, independent of global inhibition of protein synthe-
sis or cytotoxicity. The evidence for this is twofold: (1) Stx-1
can stimulate TNF production under conditions with no
detectable cellular injury or blockade of protein synthesis;
and (2) CHX, at concentrations that mildly to severely
inhibited protein synthesis or were cytotoxic, had no effect
on proximal tubule cell TNF release or mRNA accumula-
tion. The current study did not investigate the precise
Fig. 10. Effect of Stx-1 6 LPS on human
proximal tubule cell IL-6 release (A) and IL-6
mRNA levels (B). Results are expressed as
percent of control where baseline IL-6 release
was 9566 6 580 ng IL-6/mg total cell protein/24
hr and baseline IL-6 mRNA levels were 6.64 6
2.75 fg IL-6 cDNA/ng b-actin cDNA. N 5 6 per
IL-6 release data point and N 5 3 per IL-6
mRNA data point. *P , 0.05, ƒP , 0.01; both
versus control. Symbols are: (f) Stx-1 1 pg/ml;
(1) Stx 0.1 pg/ml; (M) Stx-1 0.01 pg/ml; (o) LPS;
(^) LPS/Stx-1 0.01 pg/ml.
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mechanism(s) by which Stx-1 regulates TNF production, as
this was beyond the scope of these initial investigations.
Nonetheless, there are several considerations relevant to
possible mechanisms that are of interest. First, CHX has
been reported to have no effect on TNF mRNA levels in
resting human monocytes, but to increase TNF gene tran-
scription and reduce mRNA degradation in activated
monocytes (so-called “superinduction” of mRNA) [32].
This suggests that the effect of protein synthesis inhibitors
on cytokine production may depend, in part, upon factors
modulating intrinsic cell responsiveness. For example,
CHX up-regulation of TNF in macrophages may depend
upon the ability to induce nuclear factor-kB (NF-kB) [33].
Secondly, protein synthesis inhibitors have been described
to differentially regulate intracellular signaling processes.
For example, anisomycin and CHX can act as nuclear
signaling agonists to stimulate pp35/pp15, while emitine
and puromycin do not [34]. This suggests that agents
labeled “protein synthesis inhibitors” may have cellular
effects independent of their protein synthesis’ inhibitory
Fig. 11. Effect of cycloheximide on human
proximal tubule cell IL-6 release (A) and IL-6
mRNA levels (B). Results are expressed as
percent of control where baseline IL-6 release
was 9566 6 580 ng IL-6/mg total cell protein/24
hr and baseline IL-6 mRNA levels were 6.64 6
2.75 fg IL-6 cDNA/ng b-actin cDNA. N 5 6
per IL-6 release data point and N 5 3 per IL-6
mRNA data point. ƒP , 0.01, #P , 0.001; both
versus control. Symbols are: (f) 100 mM; (u)
50 mM; (M) 10 mM; (o) 1 mM; (^) 0.1 mM.
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activity and that are specific to a given type or class of
agents. Third, protein synthesis inhibitors have been dem-
onstrated to increase mRNA and protein levels for specific
proteins while reducing overall protein synthesis. For ex-
ample, CHX increases superoxide dismutase, c-fos, c-jun,
and bcl-2 mRNAs and protein levels in neuronal cells while
reducing overall protein synthesis by up to 40% [35]. It is
evident from these considerations that Stx-1 stimulation of
TNF production may be quite complex and could poten-
tially involve mechanisms both dependent and independent
of protein synthesis inhibition.
Stx-1 increased IL-1 release and mRNA accumulation by
human proximal tubule cells. This effect occurred at toxin
concentrations ranging from not detectable to marked
inhibition of protein synthesis. In contrast to its action on
TNF, CHX had almost identical effects as Stx-1 on proxi-
mal tubule cell IL-1 production. Thus, Stx-1 stimulation of
IL-1 production appears to be a nonspecific effect resulting
from mechanisms also activated by CHX. These mecha-
nisms could be quite complex and could relate to either
global inhibition of protein synthesis and/or to other effects
of both agents. It is relevant to note that even the super-
induction of IL-1 mRNA transcripts observed in this study
could occur by a variety of mechanisms. For example,
cytokine mRNA induction by protein synthesis inhibitors
has been variously ascribed to stimulation of gene tran-
scription and/or stabilization of mRNA. Induction of IL-1
mRNA by CHX has also been found to be due to enhanced
processing of unstable IL-1 precursor transcripts into ma-
ture mRNA [36]. Detailed studies will be needed to sort
out these possibilities.
Both Stx-1 and CHX stimulated IL-6 mRNA accumula-
tion, while neither agent modified IL-6 release. Stx-1 and
CHX only stimulated IL-6 mRNA accumulation at concen-
trations that substantially inhibited protein synthesis, and
this may have prevented an increase in IL-6 translation.
Induction of IL-6 mRNA, as discussed above for the other
cytokines, could have occurred by a variety of mechanisms,
however, it is tempting to speculate that IL-6 mRNA
accumulation was a nonspecific effect associated with se-
vere cell injury.
LPS had no effect on inflammatory cytokine production
by human proximal tubule cells under baseline conditions.
This finding is supported by earlier work demonstrating
either no detectable or a small effect of LPS on proximal
tubule TNF or IL-6 production [30, 31, 37]. LPS also did
not alter Stx-1 modulation of IL-6 or TNF production;
however, the endotoxin did enhance Stx-1 stimulated IL-1
release and mRNA accumulation. LPS augmentation of
Stx-1-stimulated IL-1 production is of particular interest in
light of previous studies demonstrating that IL-1, but not
TNF or IL-6, increases proximal tubule sensitivity to the
cytotoxic effect of Stx-1 [11]. It will clearly be of interest to
determine whether LPS and Stx-1 stimulated production of
IL-1 by proximal tubules has an autocrine effect on protein
synthesis and/or cell survival.
What is the significance of Stx-1 and/or LPS elaboration
of proximal tubule cytokine production in D1HUS? Al-
though this question has not yet been answered, a large
number of possibilities exist. As alluded to earlier, these
include multiple effects of cytokines on various renal cell
types, including increases in: (1) Stx-1 cytotoxicity [6, 14];
(2) vasoactive factor release (such as endothelin-1 secretion
from glomerular endothelial cells [38]); (3) oxygen radical
formation [39]; (4) tissue factor release [40]; (5) direct
cytokine cytolytic effects [41]; (6) fibrin accumulation [42];
and (7) numerous other effects [43]. The current study has
taken the first steps, by demonstrating that proximal tubule
cells are potently stimulated by Stx-1 to produce these
inflammatory cytokines. The challenge now remains to
dissect out the role that these and possibly other cytokines
play in the pathogenesis of renal injury in D1HUS.
ACKNOWLEDGMENTS
This research was supported by NIH grants RO1 DK52043 and RO1
HL56857 (to D.E.K.).
Reprint requests to Donald E. Kohan, M.D., Ph.D., Medical Care Center
(111), Veterans Affairs Medical Center, 500 Foothill Blvd., Salt Lake City,
UT 84148, USA.
kohan.donald@salt-lake.va.gov
APPENDIX
Abbreviations used in this article are: CAT, chloramphenicol acetyl-
transferase; CHX, cycloheximide; D1HUS, diarrhea hemolytic uremic
syndrome; DMDM:F12, Dulbecco’s modified Eagle’s media:Hamm’s F12;
EIA, enzyme immunometric assay; GB3, galactose-a-1,3, galactose-B-1,4,
glucose-ceramide; IL, interleukin; LPS, lipopolysaccharide; NF-kB, nu-
clear factor-kB; PBS, phosphate buffered saline; Stx-1, Shiga toxin-1;
TCA, tricarboxylic acid; TNF, tumor necrosis factor.
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